INVESTOR RELATIONS
press release – price-sensitive
TURNOVER AS OF MARCH 31, 2026 EQUAL TO APPROXIMATELY 1.6 MILLION EUROS
TURNOVER AS OF MARCH 31, 2026 EQUAL TO APPROXIMATELY 1.6 MILLION EUROSSHAREHOLDERS’ MEETING OF ARTERRA BIOSCIENCE S.P.A.
SHAREHOLDERS’ MEETING OF ARTERRA BIOSCIENCE S.P.A.FINANCING AND GRANTING OF FUNDING FOR THE ‘RE-FOOD’ PROJECT IN THE AMOUNT OF €720,000
FINANCING AND GRANTING OF FUNDING FOR THE ‘RE-FOOD’ PROJECT IN THE AMOUNT OF €720,000PUBLICATION OF NOTICE OF CALL FOR ORDINARY SHAREHOLDERS’ MEETING
PUBLICATION OF NOTICE OF CALL FOR ORDINARY SHAREHOLDERS’ MEETINGTHE BOARD OF DIRECTORS HAS APPROVED THE DRAFT FINANCIAL STATEMENTS AS OF 31 DECEMBER 2025
THE BOARD OF DIRECTORS HAS APPROVED THE DRAFT FINANCIAL STATEMENTS AS OF 31 DECEMBER 2025TURNOVER AS OF 31 DECEMBER 2025 AMOUNTING TO €4.6 MILLION, AN INCREASE OF 11.42% COMPARED TO THE SAME PERIOD IN 2024
TURNOVER AS OF 31 DECEMBER 2025 AMOUNTING TO €4.6 MILLION, AN INCREASE OF 11.42% COMPARED TO THE SAME PERIOD IN…TRANSFER OF SHARES BY MARIA GABRIELLA COLUCCI TO SMART CAPITAL
TRANSFER OF SHARES BY MARIA GABRIELLA COLUCCI TO SMART CAPITALARTERRA BIOSCIENCE S.P.A.: TURNOVER AT SEPTEMBER 30, 2025, APPROXIMATELY 3.6 MILLION EUROS
ARTERRA BIOSCIENCE S.P.A.: TURNOVER AT SEPTEMBER 30, 2025, APPROXIMATELY 3.6 MILLION EUROSARTERRA BIOSCIENCE ANNOUNCES THE SIGNING OF THE ADDENDUM TO THE VITALAB SHAREHOLDERS’ AGREEMENT
ARTERRA BIOSCIENCE ANNOUNCES THE SIGNING OF THE ADDENDUM TO THE VITALAB SHAREHOLDERS' AGREEMENTTHE BOARD OF DIRECTORS HAS APPROVED THE HALF-YEARLY REPORT AS OF 30 JUNE 2025
THE BOARD OF DIRECTORS HAS APPROVED THE HALF-YEARLY REPORT AS OF 30 JUNE 2025
